Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PTPRC

PTPRC

Basics

Aliases:
This biomarker is also known as:
  • T200 leukocyte common antigen,
  • receptor-type tyrosine-protein phosphatase C,
  • Leukocyte common antigen,
  • T200 glycoprotein,
  • L-CA,
  • B220,
  • T200,
  • CD45 antigen,
  • CD45,
  • protein tyrosine phosphatase, receptor type, c polypeptide,
  • LCA,
  • LY5,
  • protein tyrosine phosphatase, receptor type, C,
  • CD45R,
  • EC 3.1.3.48,
  • GP180,

View in BioMuta

Description…

PTPRC is a member of the protein tyrosine phosphatase (PTP) family. Members of the PTP family are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. PTPRC is required for T-cell activation through the antigen receptor. PTPRC contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and is classified as a receptor type PTP.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

PTPRC was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html